COVID-19 and clinical research at NUH
Leading research into COVID-19
We are using our clinical research resources to lead high priority COVID-19 studies. There is currently no cure for COVID-19. Our research is making potential treatments and new developments available to our patients now to help save lives.
We are part of national and international research studies to rapidly develop new treatments and to build and share our knowledge of this virus.
Research prioritisation process
Our research is part of the national process for the prioritisation and approval of all COVID-19 research. You can find further details on this process on the National Institute for Health Research (NIHR) website.
Nottingham Health Science Partners
To coordinate COVID-19 research in Nottingham, we have established a Research Prioritisation Committee through Nottingham Health Science Partners.
Made up of our leading clinicians and academics, the Committee will review COVID-19 proposals on behalf of NUH and the University of Nottingham. Full details of the Committee's role, process and the form to submit Expressions of Interest are available in our online document library.
Finding treatments for COVID-19
We are leading a number of clinical research trials investigating potential treatments for patients. These trials involve patients who are admitted to NUH with COVID-19 or suspected COVID-19. You can find a summary of our COVID-19 research in the drop-down sections below.
Live trials for COVID-19
COVID-19 clinical trials
We are carrying out a number of trials for patients who are being treated at or admitted to NUH for COVID-19.
Our aim is to offer every patient with suspected or confirmed COVID-19 the opportunity to take part in this vital research.
Our research is part of the national and international response to COVID-19. Our expert clinical research teams are helping to find the most effective treatments:
RECOVERY - there are no specific treatments for COVID-19. This trial is investigating five different drugs, currently used for other conditions, to see if they have benefits for patients with COVID-19. The Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial will provide doctors and health services with information they need to determine which treatments should be used. Initially for adults, we have now extended this trial at NUH to include newborns, children and young people under the age of 18 years.
ISARIC - NUH is already part of the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) which is working to investigate severe acute respiratory illnesses (SARI). Data from patients at NUH suspected of having, or who are confirmed with, COVID-19 is now being included in this research.
PRIEST – this study is investigating the most effective ways of triaging people with suspected respiratory infections in emergency care during a pandemic.
REMAP-CAP – this study is identifying the most clinically effective interventions for adult patients admitted to an intensive care unit with community-acquired pneumonia and COVID-19.
GenOMICC – looking into the genetic susceptibility of patients to COVID-19 in critical care. This trial is aiming to find genetic markers which may help researchers and clinicians to identify patients who are at greater risk.
UKOSS - the UK Obstentrics Surveillance System (UKOSS) is collecting data from pregnant women who have a COVID-19 diagnosis to help understand more about how the virus may affect women and infants.
SNG001 - this trial is investigating the use of a formulation of the drug, interferon beta, in adults with COVID-19. In this trial, patients will either receive the drug or a placebo (which does not contain any active drug). The drug will be given to patients using an inhaler.
RECOVERY-RS - this trial is investigating the most effective way to administer oxygen to COVID-19 patients. Methods including CPAP and High Flow Nasal Oxygen (HFNO) are being used, comparing with more commonly used masks and nasal tubes.
ACCORD-2 - this is a national trial to fast-track the development of new drugs for treating COVID-19. It is a partnership between the NHS, the pharmaceutical industry and specialist research centres including the NIHR Nottingham Clinical Research Facility based at NUH.
Latest updates on our COVID-19 research
- Nottingham Children's Hospital pulls out the stops to enable children to take part in priority COVID-19 research trial
- NUH researchers join national study find out how COVID-19 may affect pregnant women and unborn babies
- Research Nurse Lucy Ryan explains why clinical research is no important during COVID-19 (contains video clip)
- Over 600 patients take part in international the ISARIC study for COVID-19. Intensive Cre Conusltant Dr Dan Harvey explains why this study is a priority for finding answers to the pandemic
- New study on the effects of COVID-19 for children with immune suppressed conditions
- Professor Stephen Ryder, Clinical Director of Research and Innovation thanks research staff at NUH at the end of the week when over 550 patients are recruited into trials
- Professor Guru Aithal, Gastro-Intestinal and Liver Research Theme Lead, advises patients with hypertension or diabetes on the risks of COVID-19
- COVID-19 research in Intensive Care
- Progress on our COVID-19 research, after the first 100 patients are recruited into clinical trials at NUH.
Advice to patients and carers
Some trials have been temporarily suspended as part of protecting NHS services during COVID-19.
Some trials are continuing with changes to the way the research teams work with you. For example, follow-up appointments may be carried out by phone or video conference; prescriptions may be issued electronically or medicines delivered to you at home.
Where clinically necessary, some trials are continuing to provide patients with essential treatment and care on an ongoing basis.
Where visits to our hospitals for research are continuing, these are being managed with the safety of patients and staff as our first priority. All of our research teams are following national and local guidelines for the safe delivery of healthcare services during COVID-19.
If you are involved in a clinical trial, your clinical research team will be in contact with you to discuss the next steps for you. Please do not attend for planned appointments unless your research team has confirmed this with you beforehand.
Please do not attend for any confirmed appointments if you think you have symptoms of COVID-19. Please contact your research team to rearrange your appointment, or to re-organise treatment and tests.
Our research experts are part of the national and international efforts to find effective treatments. Our aim is to offer every patient being treated at NUH for COVID-19 the opportunity to take part in this vital research. Our research teams are speaking to patients admitted to NUH with suspected or confirmed COVID-19 about taking part.
All research volunteer activities have been suspended until further notice. Thank you so much for your contributions. We will keep you updated; and once we know it is safe and appropriate to begin these activities again we will let you know.
Get in touch
If you have any questions or would like further information about our research, please email us.
Advice and information on COVID-19
If you have symptoms of coronavirus (COVID-19):
- a high temperature
- a new, continuous cough
- a new loss or change to your sense of smell or taste
the advice is to stay at home for seven days. All members of your household should remain at home for 14 days. For more health advice about COVID-19 please visit the NHS website.
For all other information and updates about the UK response to COVID-19 please visit the Government website.
If you want to know more about the science behind COVID-19 you can find the evidence and the facts on the UK Research and Innovation (UKRI) website or visit the NIHR Nottingham Biomedical Research Centre website to find out what local research experts are doing to support scientific discoveries for COVID-19.
Additional support for researchers during COVID-19
Prioritisation of COVID-19 clinical trials
There is a new prioritisation process to manage the set-up of new COVID-19 related research trials. You can find details of this process on the National Institute for Health Research (NIHR) website.
To prioritise our clinical research resources into the national COVID-19 priorities, we have established a COVID-19 Research Prioritisation Committee through Nottingham Health Science Partners. You will find full details of the Committee and the Expression of Interest form to submit your COVID-19 proposals in our COVID-19 document library.
New guidelines and protocols
Where needed locally, we will develop new guidelines and protocols for managing and amending clinical trials in the light of COVID-19 requirements. They will be published in our online document library.
Advice on your trial
Current research trials should be risk-assessed in the light of COVID-19 to ensure the safety of patients and staff. If you need help or support in managing your research trial during COVID-19 please contact a senior member of our Research Delivery Team:
Funding and grants
If you need advice and information about current research funding, grant applicatons or for research costs arising out of COVID-19 please email us.
Patient and Public Voice
We have established a COVID-19 Patient and Public Voice Taskforce to respond rapidly to requests from researchers for input and advice on COVID-19 research proposals. To request support for your trial, please email us.
Health Research Authority advice on research during COVID-19 is available on the HRA website.
MHRA advice on CTIMPS and medical device studies during COVID-19 is available online.
University of Nottingham research updates.